These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 31805529

  • 21. Mouse models for ROS1-fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency.
    Inoue M, Toki H, Matsui J, Togashi Y, Dobashi A, Fukumura R, Gondo Y, Minowa O, Tanaka N, Mori S, Takeuchi K, Noda T.
    Carcinogenesis; 2016 May; 37(5):452-60. PubMed ID: 26964870
    [Abstract] [Full Text] [Related]

  • 22. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
    Roskoski R.
    Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
    [Abstract] [Full Text] [Related]

  • 23. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
    Kimbara S, Takeda K, Fukushima H, Inoue T, Okada H, Shibata Y, Katsushima U, Tsuya A, Tokunaga S, Daga H, Okuno T, Inoue T.
    Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
    [Abstract] [Full Text] [Related]

  • 24. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
    Xu S, Wang W, Xu C, Li X, Ye J, Zhu Y, Ge T.
    BMC Cancer; 2019 Aug 05; 19(1):769. PubMed ID: 31382924
    [Abstract] [Full Text] [Related]

  • 25. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.
    Mariño-Enríquez A, Wang WL, Roy A, Lopez-Terrada D, Lazar AJ, Fletcher CD, Coffin CM, Hornick JL.
    Am J Surg Pathol; 2011 Jan 05; 35(1):135-44. PubMed ID: 21164297
    [Abstract] [Full Text] [Related]

  • 26. A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib.
    Liu W, Duan Q, Gong L, Yang Y, Huang Z, Guo H, Niu X.
    Invest New Drugs; 2021 Feb 05; 39(1):278-282. PubMed ID: 32915420
    [Abstract] [Full Text] [Related]

  • 27. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
    Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, Min YJ, Cho EK, Lee SS, Kim BS, Choi MY, Shim HS, Chung JH, La Choi Y, Lee MJ, Kim M, Kim JH, Ali SM, Ahn MJ, Cho BC.
    J Clin Oncol; 2017 Aug 10; 35(23):2613-2618. PubMed ID: 28520527
    [Abstract] [Full Text] [Related]

  • 28. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges.
    Mahajan P, Casanova M, Ferrari A, Fordham A, Trahair T, Venkatramani R.
    Curr Probl Cancer; 2021 Aug 10; 45(4):100768. PubMed ID: 34244015
    [Abstract] [Full Text] [Related]

  • 29. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
    Jiang J, Wu X, Tong X, Wei W, Chen A, Wang X, Shao YW, Huang J.
    Lung Cancer; 2018 Jan 10; 115():5-11. PubMed ID: 29290262
    [Abstract] [Full Text] [Related]

  • 30. A novel TPD52L2-ROS1 gene fusion expanding the molecular alterations in inflammatory myofibroblastic tumor: case report and literature review.
    Liu X, Duan Y, Wang G, Zhu P.
    Diagn Pathol; 2023 Sep 21; 18(1):105. PubMed ID: 37735390
    [Abstract] [Full Text] [Related]

  • 31. ROS1 fusions in cancer: a review.
    Uguen A, De Braekeleer M.
    Future Oncol; 2016 Aug 21; 12(16):1911-28. PubMed ID: 27256160
    [Abstract] [Full Text] [Related]

  • 32. Uterine inflammatory myofibroblastic tumor harboring novel NUDCD3-ROS1 and NRP2-ALK fusions: clinicopathologic features of 4 cases and literature review.
    Zhang L, Luan L, Shen L, Xue R, Huang J, Su J, Huang Y, Xu Y, Wang X, Shao Y, Ji Y, Xu C, Hou Y.
    Virchows Arch; 2023 Mar 21; 482(3):567-580. PubMed ID: 36624188
    [Abstract] [Full Text] [Related]

  • 33. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME, Choi YL, Lim SM, Deng S, Huang D, Ozeck M, Han J, Jeong JY, Shim HS, Cho BC, Kim J, Ahn MJ, Mao M.
    J Mol Diagn; 2014 Mar 21; 16(2):229-43. PubMed ID: 24418728
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. ALK-positive inflammatory myofibroblastic tumor of the abdomen with widespread microscopic multifocality.
    Lorenzi L, Cigognetti M, Medicina D, Pellegrini V, Balzarini P, Cestari R, Facchetti F.
    Int J Surg Pathol; 2014 Oct 21; 22(7):640-4. PubMed ID: 24583837
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor.
    Mai S, Xiong G, Diao D, Wang W, Zhou Y, Cai R.
    Lung Cancer; 2019 Feb 21; 128():101-104. PubMed ID: 30642440
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.